Foley Attorneys Publish on FDA's AI Medical Device Software Recommendations
May 23, 2025
MD+DI
Foley & Lardner LLP attorneys Kyle Faget, Nathan Beaver, David Rosen, and Sheridan Organ authored the MD+DI article, “FDA Outlines AI Medical Device Software Recommendations in Draft Guidance.”
The authors explore key themes from the U.S. Food and Drug Administration’s January 2024 draft guidance for developers of AI-enabled medical devices, including the FDA’s emphasis on continuous post-market monitoring, transparency, and addressing AI bias throughout the device lifecycle. They also describe important considerations for device descriptions, user interface design, risk assessment, data management, validation, and cybersecurity.
People
Related News
July 21, 2025
In the News
Nicholas O'Keefe Assesses 'Golden Share' in US Steel Deal
Foley & Lardner LLP partner Nicholas O'Keefe commented on the 'golden share' arrangement included as part of the approval of Nippon Steel's acquisition of U.S. Steel in Agenda, a Financial Times publication.
July 18, 2025
In the News
Matt Caplan Featured for Arrival to Foley – 'It's an exciting time'
Foley & Lardner LLP partner Matt Caplan is highlighted across press for his recent arrival to the firm's San Francisco office.
July 18, 2025
In the News
David Rosen on FDA's CRL Release – 'It hasn't happened in the past'
Foley & Lardner LLP partner David Rosen commented on the U.S. Food and Drug Administration's decision to publish a package of complete response letters to pharmaceutical companies in the PharmaVoice article, "Why FDA’s CRL release could open the door to lawsuits against pharma."